Jazz Pharmaceuticals
JAZZ
#2060
Rank
$7.12 B
Marketcap
$112.91
Share price
0.19%
Change (1 day)
-12.27%
Change (1 year)

P/E ratio for Jazz Pharmaceuticals (JAZZ)

P/E ratio as of June 2024 (TTM): -80.1

According to Jazz Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -80.078. At the end of 2022 the company had a P/E ratio of -45.0.

P/E ratio history for Jazz Pharmaceuticals from 2007 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-45.090.04%
2021-23.7-161.84%
202038.3136.52%
201916.2-2.56%
201816.60.33%
201716.6-0.2%
201616.6-36.48%
201526.1-85.16%
2014176416.09%
201334.1226.08%
201210.5-18.48%
201112.8-43.26%
201022.6-168.9%
2009-32.812284.8%
2008-0.2651-82.01%
2007-1.47

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
28.3-135.30%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
21.7-127.11%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.0001-100.00%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
-8.58-89.29%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.